Join to View Full Profile
111 E 210th StBronx, NY 10467
Phone+1 718-920-6006
Dr. Shi is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Duke University HospitalResidency, Pathology-Anatomic and Clinical, 2012 - 2014
University of California (Irvine)Residency, Pathology-Anatomic and Clinical, 2010 - 2014
China Medical University ShenyangClass of 1999, MD
Certifications & Licensure
NY State Medical License 2015 - 2026
CA State Medical License 2013 - 2025
NC State Medical License 2012 - 2014
American Board of Pathology Pathology - Anatomic/Pathology - Clinical- American Board of Pathology Pathology - Hematology
Publications & Presentations
PubMed
- Single-cell analysis of oncolytic virotherapy in adult T-cell leukemia/lymphoma.Jianhong An, Erqiang Hu, Yang Shi, Yanan Fang, Naijia Liu
Journal for Immunotherapy of Cancer. 2025-03-25 - The Impact of Type, Dose, and Duration of Prebiopsy Corticosteroids Use on Histomorphology and Immunohistochemical Stains in B-Cell Lymphoma: A Case-Control Study to H...Kritika Krishnamurthy, Xing Li, Jui Choudhuri, Yang Shi, Yanhua Wang
Applied Immunohistochemistry & Molecular Morphology. 2025-03-07 - Immunophenotypic, genetic, and clinical characterization of adult T-cell leukemia/lymphoma: A single tertiary care center experience in the United States.Ukuemi Edema, John Liu, Maxwell Y Ma, Kritika Krishnamurthy, Jui Choudhuri
American Journal of Clinical Pathology. 2025-02-12
Press Mentions
Everest Medicines and Gilead Sciences Jointly Announce Phase 2b Study of Sacituzumab Govitecan Conducted in China of Patients with Metastatic Triple-Negative Breast Cancer Meets Primary Overall Response Rate EndpointNovember 11th, 2021- Flock of New Folds Fills in Tauopathy Family TreeOctober 5th, 2021
- Everest Medicines Announces First Person Dosed in Global Phase 3 Registration Trial of Sacituzumab Govitecan-Hziy in China for Metastatic Urothelial CancerAugust 26th, 2021
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
